SNX281   Click here for help

GtoPdb Ligand ID: 12011

Compound class: Synthetic organic
Comment: SNX281 is a systemically active stimulator of interferon genes (STING) agonist, that was developed to induce anti-tumour immunity [1]. SNX281 is competitive with the endogenous cyclic dinucleotide STING agonist 2'3'-cGAMP. Analysis reveals that SNX281 self-dimerises to generate a structure that is large enough to occupy STING's cyclic dinucleotide binding site, which switches the protein to its active state conformation.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 84.6
Molecular weight 389.09
XLogP 7.24
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CSc1c(Cl)ccc2c1n(CC(=O)O)c1c(c2=O)ccc(c1)C(C)(C)C
Isomeric SMILES CSc1c(Cl)ccc2c1n(CC(=O)O)c1c(ccc(c1)C(C)(C)C)c2=O
InChI InChI=1S/C20H20ClNO3S/c1-20(2,3)11-5-6-12-15(9-11)22(10-16(23)24)17-13(18(12)25)7-8-14(21)19(17)26-4/h5-9H,10H2,1-4H3,(H,23,24)
InChI Key CLGJCTXUWJLYHO-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
SNX281 has been advanced as a clinical lead for solid tumours and lymphoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04609579 Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma Phase 1 Interventional Stingthera, Inc. In this study, SNX281 will be evaluated as a monotherapy and in combination with the immune checkpoint inhibitor .